Stock comparison
Amicus Therapeutics
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
FOLD
Amicus Therapeutics
Market cap
$4.55B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | FOLD | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 75B | IDXX |
| Benjamin Graham | 66D | 80A | IDXX |
| Philip Fisher |
Side-by-side metrics
| Metric | FOLD | IDXX |
|---|---|---|
| Market cap | $4.55B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | 139.7x | 31.6x |
| ROIC (TTM) | -6.46% | 40.66% |
| Gross margin | 87.91% | 62.05% |
| Net margin | -4.27% | 24.63% |
| Revenue CAGR 5y | 20.03% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
FOLD leads on
- P/E (TTM)-vs 39.0x+124%
- Revenue CAGR 5y20.03%vs 7.56%+62%
- Gross margin87.91%vs 62.05%+29%
IDXX leads on
More like IDXX
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.